SELECTED IMPORTANT SAFETY INFORMATION ABOUT JIVI, KOVALTRY, AND KOGENATE FS
You should not use JIVI, KOVALTRY, or KOGENATE FS if you are allergic to rodents (like mice and hamsters) or any ingredients in JIVI, KOVALTRY, or KOGENATE FS. ...Continue reading below

Are you a Kogenate® FS patient?

We’re here to support you.

Bayer recently announced that Kogenate FS will be discontinued. We want patients and their caregivers to know that we are here to support you during this transition. Keeping the needs of patients and caregivers in mind, Bayer has carefully considered that you will need sufficient time to consider and make decisions about your next treatment. The timing of discontinuation will vary by Kogenate FS vial size. Customer demand may lead to depletion of the larger vial sizes during the fall of 2022. Remaining Kogenate FS vial sizes are anticipated to be available into 2023. It's important to work with your healthcare provider as you consider transitioning products.

Click here for the Kogenate FS Discontinuation Announcement from Bayer.

For more information on the Kogenate FS discontinuation click below.

Kogenate FS Discontinuation

Ready for the next step?

Bayer offers the hemophilia A community additional products, as well as programs and services designed for patients and caregivers. Talk with your doctor about which product might be right for you.

    Explore all the latest offerings from Bayer
      Kogenate FS1 (to be discontinued) Kovaltry2 Jivi3
    FDA Approval 1993 2016 2018
    Who It's For (indicated age groups)

     Pediatric, adolescent and adult patients (0 - 65+) 

     Pediatric, adolescent and adult patients (0 - 65+) 

    		 Adolescent and adult patients (12 - 65+) Not for use in children under 12 years of age or in previously untreated patients
    Half-Life

     Standard half-life (SHL) 

    		 Extended half-life (EHL)
    How It's Dosed (prophylaxis highlights) Adults/Adolescents: 3 times weekly Children: Every-other-day Adults/Adolescents: 3 times weekly or twice weekly Children: Every-other-day, 3 times weekly or twice-weekly Twice-weekly starting dose, with the potential (based on bleeding episodes) to step up to every 5 days and fine tune
    Recon-stitution System

     Vial Adapter reconstitution device 

     25-gauge butterfly needle and pre-filled diluent syringe 

     25-gauge butterfly needle and pre-filled diluent syringe 
    Cell Line

     Same type of cell line 

    Kovaltry

    For children

    Learn more

    For adults and adolescents

    Learn more

    Jivi

    For adults and adolescents ≥12

    Learn more
    Father and son outside during sunset. Father and son outside during sunset.

    The Bayer Portfolio

    Delivering treatment options for hemophilia A patients and their families.

    Patient speaker smiling. Patient speaker smiling.

    Patient Stories

    Hear from real hemophilia A patients and long-time members of the Bayer family.

    Montage of Bayer representatives. Montage of Bayer representatives.

    Dedicated Support

    Connect with your dedicated Bayer Hemophilia Community Representative.

    1. Kogenate Prescribing Information. Bayer HealthCare LLC, Whippany, NJ. 2. Kovaltry Prescribing Information. Bayer HealthCare LLC, Whippany, NJ; 2021. 3. Jivi Prescribing Information. Bayer HealthCare LLC, Whippany, NJ; 2018.

    Indications and Important Safety Information

    JIVI®, KOVALTRY®, and KOGENATE® FS are injectable medicines used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.

    Indication For JIVI®

    JIVI is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you have surgery. JIVI can reduce the number of bleeding episodes in adults and adolescents with hemophilia A when used regularly (prophylaxis).

    JIVI is not for use in children below 12 years of age or in previously untreated patients.

    Indication For KOVALTRY®

    KOVALTRY is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY when you have surgery.

    Indication For Kogenate® FS

    KOGENATE FS is used to treat and control bleeding in adults and children with hemophilia A. Your healthcare provider may give you KOGENATE FS when you have surgery. KOGENATE FS can reduce the number of bleeding episodes in adults and children when used regularly (prophylaxis). KOGENATE FS can reduce the risk of joint damage in children without pre-existing joint damage when used regularly.

    JIVI, KOVALTRY, and KOGENATE FS are not indicated for the treatment of von Willebrand disease.

    Important Safety Information About JIVI, KOVALTRY, and KOGENATE FS

    • You should not use JIVI, KOVALTRY, or KOGENATE FS if you are allergic to rodents (like mice and hamsters) or any ingredients in JIVI, KOVALTRY, or KOGENATE FS.
    • Tell your healthcare provider about all the medical conditions that you have or had or are at risk of such as heart disease. 
    • Allergic reactions may occur with JIVI, KOVALTRY, and KOGENATE FS. Call your healthcare provider right away and stop treatment if you get rash or hives, itching, tightness of the chest or throat, dizziness, difficulty breathing, decrease in blood pressure, and nausea.
    • Allergic reactions to polyethylene glycol (PEG), a component of JIVI, are possible.
    • Your body can also make antibodies, called “inhibitors,” against JIVI, KOVALTRY, and KOGENATE FS, which may stop JIVI, KOVALTRY, and KOGENATE FS from working properly. Consult your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.
    • If your bleeding is not being controlled with your usual dose of JIVI, KOVALTRY, or KOGENATE FS consult your doctor immediately. You may have developed Factor VIII inhibitors to JIVI, KOVALTRY, or KOGENATE FS. If your bleeding is not being controlled with your usual dose of JIVI you may have developed antibodies to PEG and your doctor may carry out tests to confirm this.
    • The common side effects of JIVI are headache, cough, nausea, and fever.
    • The common side effects of KOVALTRY are fever, headache, and rash, in addition to inhibitors in patients who were not previously treated or minimally treated with Factor VIII products.
    • Other common side effects of KOGENATE FS are local injection site reactions (pain, swelling, irritation at infusion site) and infections from implanted injection device.
    • These are not all the possible side effects with JIVI, KOVALTRY, and KOGENATE FS. Tell your healthcare provider about any side effect that bothers you or that does not go away.

    For additional important risk and use information, please see full Prescribing Information for Jivi, Kovaltry and Kogenate FS.
     

    Kogenate<sup®</sup> FS Antihemophilic Factor (Recombinant) graphic logo. Kogenate<sup®</sup> FS Antihemophilic Factor (Recombinant) graphic logo.
    Kovaltry<sup®</sup> Antihemophilic Factor (Recombinant) graphic logo. Kovaltry<sup®</sup> Antihemophilic Factor (Recombinant) graphic logo.
    Jivi<sup®</sup> Antihemophilic Factor (Recombinant) PEGylated-aucl graphic logo. Jivi<sup®</sup> Antihemophilic Factor (Recombinant) PEGylated-aucl graphic logo.

    © 2022 Bayer. All rights reserved. Bayer, the Bayer Cross, Kogenate, Kovaltry and Jivi are registered trademarks of Bayer. Access Services by Bayer is a trademark of Bayer.

    You are encouraged to report side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

    Site last modified 5/22

    Bayer logo. Bayer logo.